Navigation Links
OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
Date:6/21/2010

alTrials/index.html.

The Principal Investigators for the SATURN trial are Dr. Tomasz Beer at the Oregon Health & Science University Knight Cancer Institute for the United States, Dr. Sebastien Hotte at Juravinski Cancer Centre in Hamilton, Ontario for Canada and Professor Karim Fizazi at the University of Paris for Europe. An Investigator meeting was held in May to train and initiate US and Canadian sites. The Company expects to initiate European sites in the third quarter of 2010.

The SATURN trial design is based on the Phase 2 data in patients with metastatic CRPC who were treated with OGX-011/ TV-1011 in combination with docetaxel/prednisone retreatment as second-line chemotherapy.

"Pain is a dominant symptom in patients with progressive prostate cancer and frequently remains a challenge despite treatment with opioid analgesics. Poorly controlled pain has devastating effects on both patients and their family members," stated Dr. Beer. "In the Phase 2 trial, almost half of patients who had pain or were on opioids and were retreated with docetaxel/prednisone with the addition of OGX-011/ TV-1011 had durable pain palliation for 12 weeks or more. This is better than expected based on pain responses seen after initial treatment with docetaxel/prednisone."

A separate Phase 2 trial evaluating OGX-011/ TV-1011 in combination with first-line chemotherapy showed that patients with advanced metastatic prostate cancer who were treated with OGX-011/ TV-1011 plus docetaxel had a median overall survival of 23.8 months compared to 16.9 months for patients treated with docetaxel alone -- a 6.9
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... , April 21, 2015 Ampio Pharmaceuticals, ... a scheduled investor call on Thursday, April 23, 4:30 ... the instructions as follows: Investor call ... number: (844) 789-4877 International toll number: (925) 418-7845 Participant ... advance to Tina Amirkiai , tina.amirkiai@fleishman.com . ...
(Date:4/21/2015)... Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or "Novogen"), ... entered into definitive agreements today to issue approximately ... 6-month option and half of one attaching 5-year ... investors in the United States ... proceeds of approximately AU$15,500,000 ("Placement"). The closing of ...
(Date:4/21/2015)... 21, 2015 A leading manufacturer of ... slated to discuss its custom fabrication services today at ... website, which launched just prior to the INTERPHEX event. ... 21, 22 and 23) at the Javits Center in ... the world’s largest and most innovative pharmaceutical and biotech ...
(Date:4/20/2015)... and Champaign, IL (PRWEB) April 20, 2015 ... the establishment of its 12th clinical research site: PMG ... Research has assumed operation of the clinical research department ... PMG’s footprint outside the Southeast to a second region ... a 150 multi-specialty physician practice enhances PMG’s access to ...
Breaking Biology Technology:Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3
... Skills Related to Nutrition Care in Mosby,s Nursing Skills ... Elsevier/MC Strategies , a pioneer in providing ... today its collaboration with the American Society for ... amend the nutrition-related skills in Mosby,s Nursing Skills. , ...
... -- Using clever but elegant design, University at Buffalo ... used to capture and purify nanomaterials. , Sculpted from ... the traps consist of tiny, organic tubes whose interior ... tubes to selectively encapsulate only positively charged particles. , ...
... & Korsinsky is investigating potential claims on behalf of ... Inc. ("PacBio" or the "Company") (NASDAQ: PACB ... For more information, click here: http://zlk.9nl.com/pacific-biosciences-california-pacb/ . ... the Company failed to disclose the following: (a) that ...
Cached Biology Technology:Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) 2Elsevier Collaborates with the American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) 3Chemists become molecular sculptors, synthesizing tiny, molecular traps 2Chemists become molecular sculptors, synthesizing tiny, molecular traps 3The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc. 2
(Date:4/9/2015)... Calif. , April 9, 2015 Synaptics ... interface solutions, announced today that it will report financial ... Thursday, April 23, 2015, after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:4/2/2015)... According to preliminary estimates Fingerprint ... higher than 125 MSEK. This exceeds the guidance provided ... revenues for Q1 2015 would be in line with ... 2014. The operating result for the first quarter is ... report will as previously communicated be published on May ...
(Date:3/31/2015)...   Guidepoint , a leading global research services ... Management TRACKER, part of the Guidepoint TRACKER ... medical device and therapeutics markets. The Post-Surgical Pain Management ... market share, and adoption rates across three major modalities ... The Post-Surgical Pain Management TRACKER will provide ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... early in pregnancy may have a profound and long-lasting effect ... lack of iron is not enough to cause severe anemia, ... in the scientific journal PLoS One . The ... mild or moderate iron deficiency, and therefore the study authors ...
... is pleased to announce the 2011 Student Research Achievement ... this competitive event held during the Biophysical Society Annual ... the Society,s subgroups selected twenty winners. The winners ... and received a monetary award. The winners are: ...
... EAST LANSING, Mich. When it comes to survival ... adaptable tortoise than a fitness-oriented hare, a Michigan State ... Science magazine, Richard Lenski, MSU Hannah Distinguished Professor ... more adaptable bacteria oriented toward long-term improvement prevailed over ...
Cached Biology News:Pre-conception and early pregnancy iron deficiency harms brain 2Pre-conception and early pregnancy iron deficiency harms brain 3In the race of life, better an adaptable tortoise than a fit hare 2
Inquire...
1M stock solution (238mg/ml)...
...
Lipofectin Reagent is the reagent of choice for some cell lines; cells of endothelial derivation transfect well with Lipofectin Reagent....
Biology Products: